Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
Kumar
D
D
Institute of Pathology, Safdarjang Hospital Campus, New Delhi, India.
Ramesh
V
V
Verma
S
S
Ramam
M
M
Salotra
P
P
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D000967:Antimony Sodium Gluconate / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D001706:Biopsy; D005260:Female; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D007898:Leishmaniasis, Visceral / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011247:Pregnancy; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine; D000666:Amphotericin B; D000967:Antimony Sodium Gluconate